Evidence map›Paper›PMID 34895259›Full record

Trial reportJournal of translational medicine2021

Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis.

José María Lamo-Espinosa, Felipe Prósper, Juan F Blanco, Fermín Sánchez-Guijo, Mercedes Alberca, Verónica García, Margarita González-Vallinas, Javier García-Sancho

Registry-linked trialAbstract readClinical TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02123368 (Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02123368 phase1 / phase2completednot on this map

Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells

TypeinterventionalSponsorClinica Universidad de Navarra, Universidad de NavarraRan2012 to 2015Enrolled30ConditionsOsteoarthritisArmsHyaluronic acid, 10 million Bone marrow mesenchimal stem cells, 100 million Bone marrow mesenchimal stem cells
3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Mesenchymal Stromal Cells for Aging Cartilage Regeneration: A Review.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Article
  8. Advances in Stem Cell-Based Therapies in the Treatment of Osteoarthritis.International journal of molecular sciences · 2023
    Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

José María Lamo-EspinosaOrthopedic Surgery and Traumatology Department, Clínica Universidad de Navarra, Pamplona, Spain.
Felipe PrósperOrthopedic Surgery and Traumatology Department, Clínica Universidad de Navarra, Pamplona, Spain.
Juan F BlancoDepartment of Traumatology, Salamanca University Hospital, Salamanca, Spain.
Fermín Sánchez-GuijoCell Therapy Area, IBSAL- Salamanca University Hospital, University of Salamanca, Salamanca, Spain.
Mercedes AlbercaUniversity of Valladolid (UVa), Valladolid, Spain.
Verónica GarcíaUniversity of Valladolid (UVa), Valladolid, Spain.
Margarita González-VallinasUniversity of Valladolid (UVa), Valladolid, Spain.
Javier García-SanchoUniversity of Valladolid (UVa), Valladolid, Spain. jgsancho@ibgm.uva.es.ORCID 0000-0003-4573-7930

Funding

Consejería de Educación, Junta de Castilla y León Centro en Red de Medicina RegenerativaConsejería de Educación, Junta de Castilla y León Escalera de Excelencia CLU-2019-02)Instituto de Salud Carlos III 0005Instituto de Salud Carlos III 0015;Instituto de Salud Carlos III PIC18/00001)Instituto de Salud Carlos III RD16/0011/0003Instituto de Salud Carlos III Red de Terapia Celular (RETIC TerCel
6 · The paper itself

Abstract

Knee osteoarthritis is the most prevalent joint disease and a frequent cause of pain, functional loss and disability. Conventional treatments have demonstrated only modest clinical benefits whereas cell-based therapies have shown encouraging results, but important details, such as dose needed, long-term evolution or number of applications required are scarcely known. Here we have reanalyzed results from two recent pilot trials with autologous bone marrow-derived mesenchymal stromal cells using the Huskisson plot to enhance quantification of efficacy and comparability. We find that cell doses of 10, 40 and 100 million autologous cells per knee provided quite similar healing results and that much of the effect attained 1 year after cell application remained after 2 and 4 years. These results are encouraging because they indicate that, apart from safety and simplicity: (i) the beneficial effect is both significant and sizeable, (ii) it can be achieved with a single injection of cells, and (iii) the effect is perdurable for years.Trial registration: EudraCT 2009-017405-11; NCT02123368. Registered 25 April 2014-Prospectively registered, https://clinicaltrials.gov/ct2/show/NCT02123368?term=02123368&draw=2&rank=1.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationOsteoarthritis, KneeBone MarrowBone Marrow CellsHumansInjections, Intra-ArticularTransplantation, AutologousTreatment OutcomeIntraarticular injectionMesenchymal stem cellsOsteoarthritisRegenerative medicineStem cell therapy

Identifiers

PMID34895259
PMCPMC8666077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.